pravastatin has been researched along with paroxetine in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 16 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Buckley, DB; Funk, RS; Hensley, T; Kazmi, F; Loewen, GJ; Parkinson, A; Pope, C | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Altman, RB; Castro, V; Denny, JC; Fernald, GH; Kohane, I; Krishnan, G; Murphy, SN; Roden, DM; Tatonetti, NP; Tsao, PS; Tsau, PS; Yue, P | 1 |
| Hampton, T | 1 |
| Altman, RB; Horvitz, E; Shah, NH; Tatonetti, NP; White, RW | 1 |
| An, L; Denduluri, S; Ravindran, PP; Renukunta, S | 1 |
| Allen, J; Bibeau, KB; Gooden, KM; Heim, JM; Irizarry, MC; Pan, X; Sampson, T; Wood, J | 1 |
| Hu, MY; Jia, LL; Li, F; Liu, C; Liu, L; Liu, XD; Xu, D; Yang, Y; Zhang, M; Zhong, ZY | 1 |
| Li, F; Ling, Z; Liu, C; Liu, L; Liu, X; Shu, N; Xu, D; Zhang, M; Zhong, Z | 1 |
| Baker, R; Jackson, D | 1 |
| Li, F; Ling, ZL; Liu, C; Liu, L; Liu, XD; Shu, N; Wang, ZJ; Zhang, M; Zhong, ZY | 1 |
1 review(s) available for pravastatin and paroxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
19 other study(ies) available for pravastatin and paroxetine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
Topics: Adrenergic beta-Antagonists; Amines; Ammonium Chloride; Antidepressive Agents, Tricyclic; Atorvastatin; Cell Line, Transformed; Diuretics; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imipramine; Lysosomes; Monensin; Nigericin; Propranolol; Pyrroles | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels.
Topics: Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Algorithms; Blood Glucose; Cohort Studies; Data Mining; Diabetes Mellitus; Drug Interactions; Electronic Health Records; Ethnicity; Female; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Paroxetine; Pravastatin; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sex Factors; Socioeconomic Factors; United States; United States Food and Drug Administration | 2011 |
Data mining approach shows promise in detecting unexpected drug interactions.
Topics: Adverse Drug Reaction Reporting Systems; Anticholesteremic Agents; Antidepressive Agents; Blood Glucose; Data Mining; Drug Interactions; Electronic Health Records; Humans; Paroxetine; Pravastatin; United States; United States Food and Drug Administration | 2011 |
Web-scale pharmacovigilance: listening to signals from the crowd.
Topics: Data Mining; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Information Storage and Retrieval; Internet; Paroxetine; Pharmacovigilance; Pravastatin; Product Surveillance, Postmarketing; ROC Curve; Selective Serotonin Reuptake Inhibitors | 2013 |
Co-medication of pravastatin and paroxetine-a categorical study.
Topics: Adult; Aged; Blood Coagulation; Blood Glucose; Carbon Dioxide; Drug Interactions; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Paroxetine; Pravastatin; Selective Serotonin Reuptake Inhibitors | 2013 |
Incidence of type 2 diabetes among patients exposed to the combination of pravastatin and paroxetine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Drug Combinations; Endpoint Determination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Insurance, Health; Male; Middle Aged; Paroxetine; Pravastatin; Retrospective Studies; Risk Assessment; Young Adult | 2015 |
Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure.
Topics: Animals; Anticholesteremic Agents; Antidepressive Agents, Second-Generation; Blood Glucose; Cell Line; Depression; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Drug Interactions; Hypercholesterolemia; Insulin; Male; Paroxetine; Pravastatin; Rats; Rats, Sprague-Dawley; Serotonin | 2014 |
Co-administration of paroxetine increased the systemic exposure of pravastatin in diabetic rats due to the decrease in liver distribution.
Topics: Administration, Intravenous; Administration, Oral; Animals; Body Fluids; Carbamates; Cell Separation; Diabetes Mellitus, Experimental; Diet, High-Fat; Disease Models, Animal; Feces; Hepatocytes; Intestinal Absorption; Liver; Male; Paroxetine; Piperidines; Pravastatin; Rats, Sprague-Dawley; Tissue Distribution | 2015 |
New models for describing outliers in meta-analysis.
Topics: Algorithms; Cognition Disorders; Cytidine Diphosphate Choline; Dental Caries; Fluorides; Humans; Hypercholesterolemia; Meta-Analysis as Topic; Models, Statistical; Monte Carlo Method; Paroxetine; Placebos; Pravastatin; Regression Analysis; Research Design; Software; Statistics as Topic; Toothpastes | 2016 |
Differential effects of pravastatin on the pharmacokinetics of paroxetine in normal and diabetic rats.
Topics: Animals; Anticholesteremic Agents; Biological Transport; Diabetes Mellitus, Experimental; Hepatocytes; Liver; Paroxetine; Pravastatin; Rats; Selective Serotonin Reuptake Inhibitors | 2017 |